Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

ed changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in it
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Sept. 18, 2014  Casen Buswell has a rare vascular ... harden.  His case is one of only 14 known cases ... only hospital in the United States , ... treatment with the dual wave-length laser, is Methodist Children,s Hospital, ... . Using a laser available in South ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... for innovation, increasing clinical development costs, new technologies ... fast-changing environment are important factors driving industry change. ... trial costs continue to rise due to a ... conducted by industry think tanks suggest each day ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin ... peer-reviewed scientific journal Diabetes, Obesity and Metabolism ... Oral-lyn™, the Company,s proprietary buccal insulin spray product. ... subjects with impaired glucose tolerance: the prevoral study , ...
... Bionovo, Inc. (Nasdaq: BNVI ), a pharmaceutical company ... women,s health and cancer, today announced that it had received ... Clinical Guidance meeting that took place on November 8, 2010. ... overall clinical development plan. "We had a ...
Cached Medicine Technology:Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 2Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 3Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 4Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 5Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4
(Date:9/19/2014)... New York (PRWEB) September 19, 2014 ... & Game Building Platform . Earlier this month Appy Pie ... Powerful Tools for the Aspiring App Developer' by Yahoo . ... which allows people to develop beautiful applications within minutes and ... development, With advanced features and support for latest mobile operating ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... escalated the fight against antibiotic-resistant bacteria on Thursday, ordering ... deal with the threat. Obama signed an ... charged with crafting a national action plan for dealing ... treatable bacteria that have become resistant to standard antibiotics ...
(Date:9/19/2014)... 2014 ShopRite has launched its new ... with the 2014-2015 school year. The new program will ... eBoxTops and special donations throughout the year. , Customers ... registering their ShopRite Price Plus Card at shopriteformyschool.com can ... favorite school. By using their Price Plus Club Card ...
(Date:9/19/2014)... September 19, 2014 The Translational ... new ND® Infusion Catheter is being used ... , The study commenced on September 4th, 2014 at ... of the new catheter demonstrated a number of advancements ... stem cells. “We are at the forefront of revolutionizing ...
(Date:9/19/2014)... QueenBeeTickets.com has the largest ticket inventory that online ... set to begin on January 21 of 2015, discount John ... secure website. , Click Here to view the ... , The Plain Spoken Tour has recently been announced, and ... a show coming to their local area. Presales have been ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2
... SEATTLE, June 5 Kagome, one of Japan,s ... natural 100 percent juice,blend have been named one of ... the help of top health experts, Health Magazine put ... the ultimate test,and unveiled a total of 75 true ...
... CHAPEL HILL, N.C., June 5 Benchmarking is not ... all economic climates. This research,excerpt presents a survey analysis ... companies on how companies are using benchmarking in a,difficult ... hot topics companies are,choosing to benchmark, the goals of ...
... brain chemical serotonin influences fat metabolism , , THURSDAY, June ... is a frustrating truism familiar to the diet-conscious choosing ... that weight control isn,t just a matter of what ... nervous system is genetically predisposed to process fat. , ...
... Presented by The Massachusetts School of,Professional Psychology, ... in this state about the ,invisible wounds of ... the stress, depression and post traumatic,stress disorder (PTSD) ... of,domestic violence and suicide. We need to begin ...
... Army Corps of,Engineers, in partnership with federal, state ... partners, will,participate in the first National Get Outdoors ... more than 75 organizations will conduct hundreds of,outdoor ... the country according to event co-sponsors, the U.S. ...
... of free health information, giveaways, entertainment and ... ... bodybuilder Chad,Gregory, along with professional fitness and figure competitors Allison,Frahn and Tina ... weekend at the Cobb Galleria Centre in Atlanta., Chad, part of ...
Cached Medicine News:Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2
... Utilized for capsulotomies, nucleus ... Formed (bent) cystitomes are angled ... of the lens, providing easier ... while reducing the potential for ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
Medicine Products: